Difference between revisions of "Part:BBa K3142008:Design"
(→References) |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | The sequence has been optimized. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used. | + | The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used. |
| − | + | ||
| − | + | ||
===Source=== | ===Source=== | ||
| Line 16: | Line 14: | ||
===References=== | ===References=== | ||
| + | Yang, J. Protein Structure Fingerprint Technology. [J] Bioinform, Genomics, Proteomics. 2018, 3(2): 1-3. | ||
Latest revision as of 22:07, 20 October 2019
Artificially designed antihypertensive pentapeptide（KYLCY）
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used.
Source
NO
References
Yang, J. Protein Structure Fingerprint Technology. [J] Bioinform, Genomics, Proteomics. 2018, 3(2): 1-3.